Short Interest in BR Biopharma, Inc. (NASDAQ:BRBI) Expands By 50.9%

BR Biopharma, Inc. (NASDAQ:BRBI) was the recipient of a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 3,543 shares, an increase of 50.9% from the July 30th total of 2,348 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 742 shares, the short-interest ratio is currently 4.8 days.

BR Biopharma Trading Up 2.9%

Shares of NASDAQ:BRBI opened at $11.01 on Thursday. The company’s fifty day moving average is $10.83. The firm has a market cap of $129.97 million and a PE ratio of 137.56. BR Biopharma has a one year low of $9.09 and a one year high of $67.01.

BR Biopharma (NASDAQ:BRBI) last released its quarterly earnings results on Tuesday, June 30th. The company reported $0.09 earnings per share for the quarter. The company had revenue of $25.13 million during the quarter.

BR Biopharma Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 4th. Investors of record on Monday, August 17th will be given a dividend of $0.1415 per share. This represents a $0.57 dividend on an annualized basis and a yield of 5.1%. The ex-dividend date is Monday, August 17th. BR Biopharma’s dividend payout ratio (DPR) is currently 525.00%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BR Biopharma stock. Acuitas Investments LLC acquired a new stake in shares of BR Biopharma, Inc. (NASDAQ:BRBI) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma accounts for about 3.2% of Acuitas Investments LLC’s holdings, making the stock its 7th largest holding.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of BR Biopharma from a “sell (e)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

BR Biopharma Company Profile

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.